Allerød, Denmark

Bent Højgaard

USPTO Granted Patents = 11 

 

Average Co-Inventor Count = 2.3

ph-index = 2

Forward Citations = 10(Granted Patents)


Location History:

  • Allerod, DK (2018)
  • Allerød, DK (2017 - 2024)

Company Filing History:


Years Active: 2017-2024

Loading Chart...
Loading Chart...
11 patents (USPTO):Explore Patents

Title: **Innovative Contributions of Bent Højgaard in Cancer Treatment**

Introduction

Bent Højgaard, an accomplished inventor based in Allerod, Denmark, has made significant strides in the pharmaceutical industry with his innovative approach to cancer treatment. His expertise lies in the development of effective drug formulations that enhance the delivery and efficacy of therapeutic agents.

Latest Patents

Højgaard holds a notable patent for a solid oral dosage form of irinotecan, a critical drug used in the treatment of cancer. The patent details a unique pharmaceutical composition that includes a specific compound known as compound (I), either as a free base or a salt. Additionally, the formulation comprises a mixture of a vehicle and a non-ionic surfactant, which plays a vital role in achieving the solubilization of the compound. The composition is also coated with an enteric coating, ensuring its effectiveness in cancer therapy.

Career Highlights

Højgaard's career is marked by his dedication to advancing pharmaceutical sciences. His role at Oncoral Pharma ApS allows him to focus on innovative drug delivery systems. His patent showcases his commitment to improving treatment options for cancer patients and demonstrates his expertise in formulating effective pharmaceutical solutions.

Collaborations

Throughout his career, Højgaard has likely collaborated with various professionals and institutions within the pharmaceutical sector to enhance the development and application of cancer treatments. While specific collaborative efforts are not detailed, his position at Oncoral Pharma ApS suggests a network of partnerships aimed at pushing the boundaries of cancer therapeutics.

Conclusion

Bent Højgaard's contributions to cancer treatment exemplify the impact of innovation in pharmaceuticals. His patented formulation of irinotecan stands as a testament to his expertise and dedication to improving patient outcomes in the fight against cancer. As he continues his work at Oncoral Pharma ApS, the potential for further innovations in drug development remains promising.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…